Roche Does Not Feel Eylea Biosimilars Will Change The Status Quo

50/50 Dynamic Of Biosimilars And Brands Expected, No Step Throughs Seen Currently

25 Oct 2024

Roche’s 2022-launched Vabysmo took no time at all to reach the coveted $1bn in sales, and the originator is continuing to feel optimistic about the newer-generation VEGF brand’s prospects, even as Amgen readies the launch of the first US biosimilar to Eylea.

Roche is not spooked by the prospect of earlier-than-anticipated biosimilar competition to Eylea (aflibercept), as it continues to back its next-generation product for wet age-related macular degeneration – the dual VEGF/Ang-2 inhibitor Vabysmo (faricimab-svoa), which has quickly soared to blockbuster status.

Earlier this week, Amgen told Generics Bulletin that it was launching the first US biosimilar to Regeneron’s earlier VEGF...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

02 Jul 2025

• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

02 Jul 2025

• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

One Month Remains To Enter GGB Awards 2025

01 Jul 2025

• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

01 Jul 2025

• By Dean Rudge

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

One Month Remains To Enter GGB Awards 2025

01 Jul 2025

• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.